A Phase I/II Open-Label, Safety And Preliminary Efficacy Study of MRX0518 in Combination with Pembrolizumab in Patients with Advanced Malignancies Who Have Progressed on PD-1/PD-L1 Inhibitors (NSCLC)

Introduction

Welcome to Sibel Blau, a leading name in clinical research and oncology treatments. We are proud to present our groundbreaking Phase I/II study that focuses on the safety and preliminary efficacy of MRX0518 in combination with Pembrolizumab for patients with advanced malignancies who have experienced progression on PD-1/PD-L1 inhibitors.

About the Study

This Phase I/II study aims to evaluate the potential of MRX0518, a novel drug, in combination with Pembrolizumab, a well-established immunotherapy drug, in treating advanced malignancies. The focus of the study is on patients who have previously progressed on PD-1/PD-L1 inhibitors, specifically in non-small cell lung cancer (NSCLC) cases.

At Sibel Blau, we understand the urgent need for innovative treatment options for patients whose conditions have not responded to existing therapies. This study offers a glimmer of hope for those who have exhausted traditional treatment avenues.

Treatment Approach

The study involves an open-label approach, meaning both the patients and the investigators are aware of the treatment received. This type of study design allows for transparency and accurate evaluation of the drug's safety and efficacy.

The combination of MRX0518 and Pembrolizumab offers a unique approach by targeting multiple pathways involved in tumor progression and immune evasion. This synergistic effect has shown promising results in preclinical and early clinical studies.

Objectives

The primary objectives of this study are to assess:

• The safety profile of the MRX0518 and Pembrolizumab combination
• The preliminary efficacy of the treatment in terms of tumor response rates
• The overall survival and progression-free survival of the patients
• The duration of response and disease control rate

Patient Eligibility

To be eligible for this study, patients must meet certain criteria:

• Diagnosis of advanced malignancy, specifically non-small cell lung cancer
• Progression on PD-1/PD-L1 inhibitors
• Adequate organ function and performance status
• Availability for regular follow-up visits

Trial Process

Patients participating in this study will undergo a comprehensive screening process to ensure their eligibility. Once enrolled, they will receive the MRX0518 and Pembrolizumab combination treatment as per the study protocol.

Regular follow-up visits will be scheduled to monitor the patients' response to the treatment and any observed side effects. Close collaboration between patients and our experienced team of oncologists will ensure the highest level of care throughout the trial process.

Expected Outcomes

We anticipate that this Phase I/II study will provide valuable insights into the safety and efficacy of the MRX0518 and Pembrolizumab combination in patients with advanced malignancies who have experienced progression on PD-1/PD-L1 inhibitors. The results obtained will guide future research and potentially open up new avenues for personalized cancer treatments.

Contact Us

If you are interested in learning more about this study or have any questions, please do not hesitate to reach out to our dedicated team at Sibel Blau. We are here to offer support, answer your queries, and provide the necessary information to help you make informed decisions regarding your treatment options.

We look forward to embarking on this transformative journey with you as we strive to make significant advancements in the field of oncology.